Galectins as modulators of tumor progression in head and neck squamous cell carcinomas

Head and neck squamous cell carcinomas (HNSCCs) remain a significant cause of morbidity worldwide. Biological therapies able to induce and/or upregulate antitumor immune responses could represent a complementary approach to conventional treatments for patients with HNSCC because, despite advances in...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2007-09, Vol.29 (9), p.874-884
Main Authors: Saussez, Sven, Camby, Isabelle, Toubeau, Gerard, Kiss, Robert
Format: Article
Language:English
Subjects:
Antitumor activity
Biological and medical sciences
cancer
Carcinoma, Squamous Cell - epidemiology
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - immunology
Carcinoma, Squamous Cell - physiopathology
Carcinoma, Squamous Cell - surgery
Cell death
Cell migration
Cell Movement - physiology
Cell proliferation
Chemotherapy
Disease Progression
galectin
Galectin 1 - metabolism
Galectin 1 - physiology
Galectin 3 - metabolism
galectin-1
Galectins - metabolism
Galectins - physiology
Head
head and neck
Head and neck cancer
Head and Neck Neoplasms - epidemiology
Head and Neck Neoplasms - genetics
Head and Neck Neoplasms - immunology
Head and Neck Neoplasms - physiopathology
Humans
Immune response
Immune system
Immunohistochemistry
Immunotherapy
Medical sciences
Morbidity
Neck
Otorhinolaryngology (head neck, general aspects and miscellaneous)
Otorhinolaryngology. Stomatology
Prognosis
Radiotherapy
squamous cell carcinoma
Surgery
T-Lymphocytes - physiology
tumor progression
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Head and neck squamous cell carcinomas (HNSCCs) remain a significant cause of morbidity worldwide. Biological therapies able to induce and/or upregulate antitumor immune responses could represent a complementary approach to conventional treatments for patients with HNSCC because, despite advances in surgery, radiotherapy, and chemotherapy, the overall survival rates for these patients have not changed over recent decades. Galectins are involved in the control of cell proliferation, cell death, and cell migration and in the modulation of various functions of the immune system. In this context, galectin‐1 is known to protect HNSCCs from the immune system. The present review details the involvement of galectins in HNSCC biology and suggests a number of approaches to reduce the levels of expression of galectin‐1 in HNSCCs, with the aim of improving the efficiency of HNSCC immunotherapy. © 2007 Wiley Periodicals, Inc. Head Neck, 2007
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.20559